Gold bars to be exempt from tariffs, White House clarifies
SAN DIEGO—Jill Marie Broadfoot, the Chief Financial Officer of aTyr Pharma Inc (NASDAQ:ATYR), recently sold a portion of her holdings in the company. According to a recent SEC filing, Broadfoot sold 1,254 shares of common stock on February 4, 2025, at a price of $3.78 per share, totaling approximately $4,740. The transaction comes as aTyr’s stock has shown remarkable strength, with a 108% gain over the past six months and a market capitalization of $318 million, according to InvestingPro data.
The sale was made to satisfy tax withholding obligations related to the partial vesting of restricted stock units (RSUs) that were granted on February 3, 2022. Following this transaction, Broadfoot now holds 31,763 shares of aTyr Pharma’s common stock.
Earlier, on February 3, 2025, Broadfoot acquired 3,750 shares through the vesting of RSUs, which converted into common stock on a one-for-one basis. This acquisition was part of a previously scheduled vesting plan.
In other recent news, aTyr Pharma has been making notable strides in its operations. Following a thorough review of third-quarter 2024 earnings and year-end 2024 data, Piper Sandler identified aTyr Pharma as one of the six companies with de-risked Phase 3 readouts or interim analyses expected in 2025. The investment bank also highlighted the potential catalysts that could impact biotechnology firms into 2025.
Further, aTyr Pharma recently expanded its stock sale agreement with Jefferies LLC, allowing for the potential sale of additional common stock shares. This amendment to the existing sales agreement provides a framework for potential additional sales, although it does not obligate aTyr Pharma to sell any shares.
In addition to financial developments, aTyr Pharma has also expanded its board with the appointment of Eric Benevich, the Chief Commercial Officer at Neurocrine (NASDAQ:NBIX) Biosciences, Inc. His extensive pharmaceutical commercial experience is expected to be a valuable asset to aTyr as it advances towards the commercialization phase.
Lucid (NASDAQ:LCID) Capital Markets initiated coverage on aTyr Pharma with a Buy rating, noting the potential of Efzofitimod, aTyr Pharma’s lead candidate currently in a Global Phase 3 EFZO-FIT trial for Pulmonary Sarcoidosis. The firm highlighted that aTyr Pharma is approaching significant milestones that could act as catalysts for the company. These are the recent developments for aTyr Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.